scispace - formally typeset
W

Walter Berger

Researcher at Medical University of Vienna

Publications -  396
Citations -  16667

Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.

Papers
More filters
Journal ArticleDOI

Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds.

TL;DR: Thiol-induced intracellular ROS generation might contribute to the anticancer activity of copper thiosemicarbazone complexes but is not the determining factor, while experiments on generation of oxidative stress and the influence of biologically relevant reductants revealed that reductant-dependent redox cycling occurred mainly outside the cells.
Journal ArticleDOI

Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells.

TL;DR: The results suggest that short-term exposure to very low ENN concentrations, for example, via food intake, might have tumor-promoting functions based on growth stimulation, suggesting a potential quality of ENN as an anticancer drug.
Journal ArticleDOI

Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.

TL;DR: In this paper, the eEF1A targeting with narciclasine (50 nM) leads to marked actin cytoskeleton disorganization, resulting in cytokinesis impairment, and protein synthesis impairment (elongation and initiation steps), whereas apoptosis is induced at higher doses only (≥200 nM).
Journal ArticleDOI

Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

TL;DR: The results suggest that Spry2 plays a role as tumor suppressor in NSCLC by antagonizing receptor tyrosine kinase–induced signaling at different levels, indicating feasibility for the usage of Spry in targeted gene therapy of NSCLCs.